CRISPR/$CRSP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- Ticker
- $CRSP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 393
- Headquarters
- Zug, Switzerland
- Website
- www.crisprtx.com
CRISPR Metrics
BasicAdvanced
$3.9B
-
-$4.75
1.90
-
Price and volume
Market cap
$3.9B
Beta
1.9
52-week high
$63.45
52-week low
$39.80
Average daily volume
1.8M
Financial strength
Current ratio
16.211
Quick ratio
16.122
Long term debt to equity
0.462
Total debt to equity
0.473
Profitability
EBITDA (TTM)
-499.68
Gross margin (TTM)
-1,776.48%
Net profit margin (TTM)
-1,812.07%
Operating margin (TTM)
-2,058.55%
Effective tax rate (TTM)
-0.55%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-13.49%
Return on equity (TTM)
-25.60%
Valuation
Price to revenue (TTM)
153.532
Price to book
2.36
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
-10.214
Free cash flow yield (TTM)
-9.79%
Free cash flow per share (TTM)
-3.935
Growth
Revenue change (TTM)
-34.34%
Earnings per share change (TTM)
-14.95%
3-year revenue growth (CAGR)
-47.10%
10-year revenue growth (CAGR)
23.43%
3-year earnings per share growth (CAGR)
1.94%
10-year earnings per share growth (CAGR)
-6.84%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Analyst projections of the future price of CRISPR stock.
Bulls say / Bears say
CASGEVY sales reached $99 million in Q3 2026, up 30% quarter on quarter and nearly sixfold year on year. It is approved in 39 countries, with approvals for younger children widening its potential patient pool. (CRISPR Therapeutics)
In a Phase 1b study of severe hypertriglyceridaemia, CTX310 cut triglycerides by a mean 63% at day 30; earlier Phase 1a data showed lipid reductions lasting a year. These early results offer a potential growth driver beyond CASGEVY. (CRISPR Therapeutics, CRISPR Therapeutics)
Early Phase 1 results for zugo-cel showed response signals in autoimmune diseases, and the company said it had been well tolerated in all 21 patients treated. This gives CRISPR another potentially valuable pipeline avenue, although the evidence is still early. (Investing.com, CRISPR Therapeutics)
The CASGEVY patient journey can be slow: company management said it may take more than six months, and sometimes nine months or longer, from treatment initiation to infusion. That can delay the conversion of patient starts into treated patients and sales. (Stock Analysis)
CRISPR reported $12.7 million in total revenue and a $111.4 million net loss in Q3, despite CASGEVY’s $99 million in sales with Vertex. Commercial growth has yet to deliver profitability for CRISPR. (U.S. Securities and Exchange Commission, Morningstar)
Vertex controls CASGEVY’s global development, manufacturing and commercialisation, and receives 60% of its profits, leaving CRISPR with 40% and limited control over its only marketed therapy. This makes near-term commercial returns dependent on a partner and limits how much of the product’s success CRISPR captures. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRISPR News
AllArticlesVideos
Funds containing CRISPR
Fund name | Fund size | $CRSP weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $129M | 4.97% |
ARK Genomic Revolution£ARCG | $129M | 4.97% |
ARK Innovation€ARXK | $294M | 4.45% |
ARK Innovation£ARCK | $294M | 4.45% |
iShares Ageing Population£AGES | $887M | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


